mRNA |
triazolothiadiazine |
CTRPv2 |
pan-cancer |
AAC |
-0.088 |
0.008 |
mRNA |
ISOX:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.1 |
0.008 |
mRNA |
BRD-K71935468 |
CTRPv2 |
pan-cancer |
AAC |
0.11 |
0.008 |
mRNA |
VX-11e |
GDSC1000 |
pan-cancer |
AAC |
-0.1 |
0.009 |
mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.11 |
0.009 |
mRNA |
Obatoclax Mesylate |
GDSC1000 |
pan-cancer |
AAC |
-0.1 |
0.009 |
mRNA |
TGX221 |
CTRPv2 |
pan-cancer |
AAC |
0.11 |
0.01 |
mRNA |
selumetinib:GDC-0941 (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.1 |
0.01 |
mRNA |
Cytarabine |
GDSC1000 |
pan-cancer |
AAC |
-0.1 |
0.01 |
mRNA |
triptolide |
CTRPv2 |
pan-cancer |
AAC |
-0.1 |
0.01 |